Compare YAAS & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YAAS | XBIO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 5.9M |
| IPO Year | 2024 | N/A |
| Metric | YAAS | XBIO |
|---|---|---|
| Price | $1.61 | $2.44 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 137.5K | 47.3K |
| Earning Date | 07-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $581,862.00 | ★ $2,858,935.00 |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.30 |
| 52 Week Low | $1.30 | $2.20 |
| 52 Week High | $560.00 | $13.93 |
| Indicator | YAAS | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 40.78 |
| Support Level | $1.30 | $2.31 |
| Resistance Level | $2.30 | $2.64 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 31.00 | 31.65 |
Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere. Geographically operates in PRC, Hong Kong, and Cayman Island.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.